Global cancer statistics, 2002
- PMID: 15761078
- DOI: 10.3322/canjclin.55.2.74
Global cancer statistics, 2002
Abstract
Estimates of the worldwide incidence, mortality and prevalence of 26 cancers in the year 2002 are now available in the GLOBOCAN series of the International Agency for Research on Cancer. The results are presented here in summary form, including the geographic variation between 20 large "areas" of the world. Overall, there were 10.9 million new cases, 6.7 million deaths, and 24.6 million persons alive with cancer (within three years of diagnosis). The most commonly diagnosed cancers are lung (1.35 million), breast (1.15 million), and colorectal (1 million); the most common causes of cancer death are lung cancer (1.18 million deaths), stomach cancer (700,000 deaths), and liver cancer (598,000 deaths). The most prevalent cancer in the world is breast cancer (4.4 million survivors up to 5 years following diagnosis). There are striking variations in the risk of different cancers by geographic area. Most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Similar articles
-
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.Int J Cancer. 2015 Mar 1;136(5):E359-86. doi: 10.1002/ijc.29210. Epub 2014 Oct 9. Int J Cancer. 2015. PMID: 25220842
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516. Int J Cancer. 2010. PMID: 21351269
-
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. CA Cancer J Clin. 2018. PMID: 30207593
-
International variation.Oncogene. 2004 Aug 23;23(38):6329-40. doi: 10.1038/sj.onc.1207726. Oncogene. 2004. PMID: 15322508 Review.
-
Global cancer statistics in the year 2000.Lancet Oncol. 2001 Sep;2(9):533-43. doi: 10.1016/S1470-2045(01)00486-7. Lancet Oncol. 2001. PMID: 11905707 Review.
Cited by
-
A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.Invest New Drugs. 2013 Aug;31(4):910-7. doi: 10.1007/s10637-012-9895-6. Epub 2012 Nov 20. Invest New Drugs. 2013. PMID: 23179335 Free PMC article. Clinical Trial.
-
Dendritic Cell (DC) Vaccine in Mouse Lung Cancer Minimal Residual Model; Comparison of Monocyte-derived DC vs. Hematopoietic Stem Cell Derived-DC.Immune Netw. 2012 Dec;12(6):269-76. doi: 10.4110/in.2012.12.6.269. Epub 2012 Dec 31. Immune Netw. 2012. PMID: 23396889 Free PMC article.
-
Downstaging advanced hepatocellular carcinoma to the Milan criteria may provide a comparable outcome to conventional Milan criteria.J Gastrointest Surg. 2013 Aug;17(8):1440-6. doi: 10.1007/s11605-013-2229-y. Epub 2013 May 30. J Gastrointest Surg. 2013. PMID: 23719776
-
Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation.Oncotarget. 2015 Jun 30;6(18):15940-52. doi: 10.18632/oncotarget.3612. Oncotarget. 2015. PMID: 25909284 Free PMC article.
-
Association of interleukin-10 promoter polymorphism (-1082 g/a) and gastric cancer in andhra pradesh population of South India.Iran J Cancer Prev. 2012 Summer;5(3):117-23. Iran J Cancer Prev. 2012. PMID: 25628830 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical